Qu Biologics is a clinical stage company that is at the forefront of a paradigm shift in the way we treat cancer and other immune-related disease. Rather than blocking or stimulating a single specific receptor or pathway, the company’s Site Specific Immunomodulators (SSIs), a novel class of immunotherapies, aims to restore the full breadth of the body’s normal immune response in a targeted organ. SSIs, which act as innate immune vaccines, are designed to activate the body’s innate immune response and to safely restore normal immune function in a targeted organ or tissue and correct the immune dysregulation and chronic inflammation underlying many chronic diseases including cancer, inflammatory bowel disease and other immune-related conditions. Qu has demonstrated proof of principle for its proprietary SSI Platform for the prevention and treatment of a wide range of cancers, infections, and chronic inflammatory diseases. Qu has completed Health Canada-approved Phase 2 clinical trials in Crohn’s disease, ulcerative colitis, and recurrent lung cancer and has three active Phase 2 clinical trials in colon cancer and immunosenescense.
For more information on current trials and updates, please visit www.qubiologics.com.